Immunochem

Executive Summary

Immunochem is a Belgian biotechnology company founded in 1998, specializing in AI-driven antibody discovery. Its proprietary EVOBodies™ platform leverages artificial intelligence and biological tools to generate single-domain antibodies (VHH) and minibinders for research and diagnostic applications. The company targets bio-pharmaceutical researchers, offering a predictable 6-week process to create binding molecules against challenging antigens. Despite a long history, Immunochem remains privately held with limited public financial information, suggesting a niche but stable position in the antibody discovery market. The company's focus on AI-driven discovery aligns with industry trends, but its low profile and lack of disclosed partnerships or funding rounds indicate a conservative growth trajectory. With a strong foundation in diagnostics and research tools, Immunochem is well-positioned to capitalize on the growing demand for custom antibodies, though its impact on therapeutics remains to be seen.

Upcoming Catalysts (preview)

• Q3 2026Expansion of EVOBodies™ Platform into New Therapeutic Areas40% success
• Q4 2026Strategic Partnership with a Major Pharma Company30% success
• Q1 2027Launch of a New Diagnostic Product Targeting Infectious Diseases50% success